InvestSMART

Innate Immunotherapeutics Limited (ASX: IIL) - Announcements

Current share price for IIL : $0.360 0.02 (5.88%)+

ASX company news and announcements for Innate Immunotherapeutics Limited (IIL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Innate Immunotherapeutics Limited (IIL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Innate Immunotherapeutics Limited (IIL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Innate Immunotherapeutics Limited (IIL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Results of Meeting - Annual General Meeting 30 Aug 2017 11:56AM $0.039 $0.360 risen by 823.08%
- App 4C - Quarterly Statement of Cashflows - June 2017 Qtr 28 Jul 2017 9:01AM $0.054 $0.360 risen by 566.67%
- App 4G - Key to Corporate Governance Disclosures 28 Jul 2017 8:34AM $0.054 $0.360 risen by 566.67%
- 2017 Corporate Governance Statement 28 Jul 2017 8:33AM $0.054 $0.360 risen by 566.67%
- Annual Report to Shareholders - YE 31 March 2017 27 Jul 2017 6:52PM $0.054 $0.360 risen by 566.67%
- Notice of Annual General Meeting/Proxy Form 27 Jul 2017 6:50PM $0.054 $0.360 risen by 566.67%
- Change of Director's Interest Notice - Simon Wilkinson 24 Jul 2017 8:27AM $0.049 $0.360 risen by 634.69%
- No Change in Trial Outcome Following Additional Analysis 21 Jul 2017 8:37AM $0.054 $0.360 risen by 566.67%
- Response to ASX Price Query 11 Jul 2017 4:26PM $0.061 $0.360 risen by 490.16%
- Change of Director's Interest Notice - A. Sneddon 29 Jun 2017 5:32PM $0.081 $0.360 risen by 344.44%
- Change of Director's Interest Notice - M. Quinn 29 Jun 2017 5:28PM $0.081 $0.360 risen by 344.44%
- Top-Line Results for Trial of MIS416 27 Jun 2017 9:11AM $0.640 $0.360 fallen by 43.75%
- Trading Halt 23 Jun 2017 12:53AM $0.640 $0.360 fallen by 43.75%
- Full Year Statutory Accounts - Year Ended 31 March 2017 22 Jun 2017 12:35AM $0.655 $0.360 fallen by 45.04%
- FDA Clearance - MIS416 Investigational New Drug Application 21 Jun 2017 8:35AM $0.655 $0.360 fallen by 45.04%
- Preliminary Final Report - Year Ended 31 March 2017 31 May 2017 8:44AM $0.735 $0.360 fallen by 51.02%
- American Academy of Neurologists Posters & KOL Presentation 1 May 2017 9:43AM $0.765 $0.360 fallen by 52.94%
- Appendix 4C - March 17 Quarter Statement of Cash Flows 28 Apr 2017 9:57AM $0.785 $0.360 fallen by 54.14%
- Completion of Phase 2B Trial of MIS416 20 Apr 2017 8:32AM $0.800 $0.360 fallen by 55%
- Grant of Options to Chief Executive Officer 19 Apr 2017 2:35PM $0.805 $0.360 fallen by 55.28%
- Section 708A Cleansing Statement - Placement 24 Mar 2017 9:52AM $0.775 $0.360 fallen by 53.55%
- Appendix 3B - Placement 24 Mar 2017 9:51AM $0.775 $0.360 fallen by 53.55%
- Private Placement to raise Additional Working Capital 17 Mar 2017 9:08AM $0.785 $0.360 fallen by 54.14%
- Trading Halt 16 Mar 2017 9:21AM $0.785 $0.360 fallen by 54.14%
- S&P DJ Indices Announces March Quarterly Rebalance 10 Mar 2017 8:19AM $0.670 $0.360 fallen by 46.27%

51 - 75 of 191 results

Page 3 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.